Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 449

1.

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.

Boudewijns S, Bloemendal M, de Haas N, Westdorp H, Bol KF, Schreibelt G, Aarntzen EHJG, Lesterhuis WJ, Gorris MAJ, Croockewit A, van der Woude LL, van Rossum MM, Welzen M, de Goede A, Hato SV, van der Graaf WTA, Punt CJA, Koornstra RHT, Gerritsen WR, Figdor CG, de Vries IJM.

Cancer Immunol Immunother. 2020 Jan 24. doi: 10.1007/s00262-019-02466-x. [Epub ahead of print]

PMID:
31980913
2.

Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial.

Poort H, Peters MEWJ, van der Graaf WTA, Nieuwkerk PT, van de Wouw AJ, Nijhuis-van der Sanden MWG, Bleijenberg G, Verhagen CAHHVM, Knoop H.

Ann Oncol. 2020 Jan;31(1):115-122. doi: 10.1016/j.annonc.2019.09.002.

PMID:
31912784
3.

Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.

Ham JC, van Meerten E, Fiets WE, Beerepoot LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der Graaf WTA, van Herpen CML.

Head Neck. 2020 Jan 6. doi: 10.1002/hed.26053. [Epub ahead of print]

PMID:
31903657
4.

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.

Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP; Dutch Pharmacology and Oncology Group (DPOG).

Br J Clin Pharmacol. 2019 Nov 28. doi: 10.1111/bcp.14185. [Epub ahead of print] Review.

PMID:
31782166
5.

A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours.

Martin E, Coert JH, Flucke UE, Slooff WM, Ho VKY, van der Graaf WT, van Dalen T, van de Sande MAJ, van Houdt WJ, Grünhagen DJ, Verhoef C.

Eur J Cancer. 2020 Jan;124:77-87. doi: 10.1016/j.ejca.2019.10.014. Epub 2019 Nov 21.

6.

Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas.

Weidema ME, Flucke UE, van der Graaf WTA, Ho VKY, Hillebrandt-Roeffen MHS; Dutch Nationwide Network and Registry of Histo- and Cytopathology (PALGA)-Group, Versleijen-Jonkers YMH, Husson O, Desar IME.

Cancers (Basel). 2019 Nov 12;11(11). pii: E1780. doi: 10.3390/cancers11111780.

7.

The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.

Husson O, de Rooij BH, Kieffer J, Oerlemans S, Mols F, Aaronson NK, van der Graaf WTA, van de Poll-Franse LV.

Oncologist. 2019 Oct 31. pii: theoncologist.2019-0348. doi: 10.1634/theoncologist.2019-0348. [Epub ahead of print] Review.

8.

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.

Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA.

Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y.

9.

DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas.

Weidema ME, van de Geer E, Koelsche C, Desar IME, Kemmeren P, Hillebrandt-Roeffen MHS, Ho VKY, van der Graaf WTA, Versleijen-Jonkers YMH, von Deimling A, Flucke UE; PALGA Group.

Clin Cancer Res. 2020 Jan 1;26(1):93-100. doi: 10.1158/1078-0432.CCR-19-2180. Epub 2019 Sep 27.

PMID:
31562204
10.

Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance.

van Houdt WJ, Husson O, Patel A, Jones RL, Smith MJF, Miah AB, Messiou C, Moskovic E, Al-Muderis O, Benson C, Zaidi S, Dunlop A, Strauss DC, Hayes AJ, van der Graaf WTA.

Ann Surg Oncol. 2019 Dec;26(13):4699-4706. doi: 10.1245/s10434-019-07826-6. Epub 2019 Sep 17.

PMID:
31531797
11.

Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study.

Ham JC, van Herpen CML, Driessen CML, van der Graaf WTA, Husson O.

Oral Oncol. 2019 Sep;96:105-112. doi: 10.1016/j.oraloncology.2019.07.014. Epub 2019 Jul 17.

12.

[Care for adolescents and young adults with cancer; the role of a national platform].

van der Graaf WTA, Jansen R, Manten-Horst E.

Ned Tijdschr Geneeskd. 2019 Jul 23;163. pii: D3767. Dutch.

PMID:
31361419
13.

Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre.

Drabbe C, Benson C, Younger E, Zaidi S, Jones RL, Judson I, Chisholm J, Mandeville H, Fisher C, Thway K, Al Muderis O, Messiou C, Strauss D, Husson O, Miah A, Van der Graaf WTA.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e27-e35. doi: 10.1016/j.clon.2019.07.007. Epub 2019 Jul 23.

PMID:
31350181
14.

Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).

Den Hollander D, Van der Graaf WTA, Desar IME, Le Cesne A.

Acta Oncol. 2019 Nov;58(11):1648-1654. doi: 10.1080/0284186X.2019.1637017. Epub 2019 Jul 26.

PMID:
31345082
15.

The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.

Lubberman FJE, van der Graaf WTA, Xu L, Cleton A, Demetri GD, Gelderblom H, van Erp NP.

Br J Clin Pharmacol. 2019 Oct;85(10):2399-2404. doi: 10.1111/bcp.14061. Epub 2019 Aug 19.

16.

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients.

Verboom MC, Gelderblom H, Kerst JM, Steeghs N, Reyners AKL, Sleijfer S, van der Graaf WTA, van den Hout WB.

Sarcoma. 2019 Jun 2;2019:3234205. doi: 10.1155/2019/3234205. eCollection 2019.

17.

Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.

Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee TC, Heskamp S, Hoekstra OS, Verheul H, van der Veldt AAM, de Vries EGE, Boerman OC, van der Graaf WTA, Oyen WJG, van Herpen CML.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1931-1939. doi: 10.1007/s00259-019-04358-9. Epub 2019 Jun 6.

18.

The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (DIET Study).

Lubberman FJE, Gelderblom H, Hamberg P, Vervenne WL, Mulder SF, Jansman FGA, Colbers A, van der Graaf WTA, Burger DM, Luelmo S, Moes DJAR, van Herpen CML, van Erp NP.

Clin Pharmacol Ther. 2019 Nov;106(5):1076-1082. doi: 10.1002/cpt.1515. Epub 2019 Jul 9.

PMID:
31125423
19.

Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease.

Weidema ME, Versleijen-Jonkers YMH, Flucke UE, Desar IME, van der Graaf WTA.

Crit Rev Oncol Hematol. 2019 Jun;138:120-131. doi: 10.1016/j.critrevonc.2019.04.010. Epub 2019 Apr 15. Review.

20.

Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).

Driessen CM, Ham JC, Te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, van Herpen CM.

Cancers (Basel). 2019 Apr 17;11(4). pii: E551. doi: 10.3390/cancers11040551.

21.

Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.

Ham JC, Driessen CM, Hendriks MP, Fiets E, Kreike B, Hoeben A, Slingerland M, van Opstal CC, Kullberg BJ, Jonker MA, Adang EM, Kaanders JH, van der Graaf WT, van Herpen CM.

Eur J Cancer. 2019 May;113:32-40. doi: 10.1016/j.ejca.2019.02.013. Epub 2019 Apr 6.

PMID:
30965213
22.

Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas.

Vlenterie M, Oyen WJ, Steeghs N, Desar IME, Verheijen RB, Koenen AM, Grootjans W, DE Geus-Oei LF, VAN Erp NP, VAN DER Graaf WT.

Anticancer Res. 2019 Mar;39(3):1309-1316. doi: 10.21873/anticanres.13243.

PMID:
30842163
23.

Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.

Vos M, Sleijfer S, Litière S, Touati N, Duffaud F, van der Graaf WT, Gelderblom H.

Acta Oncol. 2019 Jun;58(6):872-879. doi: 10.1080/0284186X.2019.1581376. Epub 2019 Mar 4.

PMID:
30831041
24.

The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function.

Verspoor FGM, Mastboom MJL, Hannink G, van der Graaf WTA, van de Sande MAJ, Schreuder HWB.

Bone Joint J. 2019 Mar;101-B(3):272-280. doi: 10.1302/0301-620X.101B3.BJJ-2018-0804.R1.

PMID:
30813787
25.

Caregivers' burden and fatigue during and after patients' treatment with concomitant chemoradiotherapy for locally advanced head and neck cancer: a prospective, observational pilot study.

Langenberg SMCH, van Herpen CML, van Opstal CCM, Wymenga ANM, van der Graaf WTA, Prins JB.

Support Care Cancer. 2019 Nov;27(11):4145-4154. doi: 10.1007/s00520-019-04700-9. Epub 2019 Feb 22.

26.

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials.

Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen RHJ, Van Erp NP, Gelderblom H, Van der Graaf WT, Gronchi A.

Clin Cancer Res. 2019 Mar 1;25(5):1479-1485. doi: 10.1158/1078-0432.CCR-18-2748. Epub 2019 Feb 14.

PMID:
30765389
27.

Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.

Sebio A, Constantinidou A, Benson C, Antoniou G, Messiou C, Miah A, Zaidi S, Petruckevitch A, Al-Muderis O, Thway K, VAN DER Graaf WT, Jones RL.

Anticancer Res. 2019 Jan;39(1):347-351. doi: 10.21873/anticanres.13118.

PMID:
30591479
28.

Online support community for adolescents and young adults (AYAs) with cancer: user statistics, evaluation, and content analysis.

Kaal SE, Husson O, van Dartel F, Hermans K, Jansen R, Manten-Horst E, Servaes P, van de Belt TH, Engelen LJ, Prins JB, Verberne S, van der Graaf WT.

Patient Prefer Adherence. 2018 Dec 6;12:2615-2622. doi: 10.2147/PPA.S171892. eCollection 2018.

29.

Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.

Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R, van Herpen CML.

Head Neck. 2019 Feb;41(2):488-494. doi: 10.1002/hed.25434. Epub 2018 Dec 7.

PMID:
30536479
30.

Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry.

Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ, Desar IME, van der Graaf WTA, Bonenkamp JJ, Reyners AKL, van Etten B.

Eur J Surg Oncol. 2019 Mar;45(3):410-415. doi: 10.1016/j.ejso.2018.09.013. Epub 2018 Oct 16.

PMID:
30416078
31.

Age-related sarcoma patient experience: results from a national survey in England.

Younger E, Husson O, Bennister L, Whelan J, Wilson R, Roast A, Jones RL, van der Graaf WT.

BMC Cancer. 2018 Oct 17;18(1):991. doi: 10.1186/s12885-018-4866-8.

32.

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310. No abstract available.

33.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321. No abstract available.

34.

Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden.

Langenberg SMCH, Reyners AKL, Wymenga ANM, Sieling GCM, Veldhoven CMM, van Herpen CML, Prins JB, van der Graaf WTA.

Acta Oncol. 2019 Feb;58(2):191-199. doi: 10.1080/0284186X.2018.1518592. Epub 2018 Oct 3.

PMID:
30280630
35.

Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management.

Owen C, Constantinidou A, Miah AB, Thway K, Fisher C, Benson C, Zaidi S, Messiou C, VAN DER Graaf WTA, Jones RL.

Anticancer Res. 2018 Sep;38(9):5275-5282. doi: 10.21873/anticanres.12853. Review.

PMID:
30194178
36.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267. doi: 10.1093/annonc/mdy320. No abstract available.

37.

Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma.

Chew W, Benson C, Thway K, Hayes A, Miah A, Zaidi S, Lee ATJ, Messiou C, Fisher C, van der Graaf WT, Jones RL.

Med Oncol. 2018 Sep 5;35(11):138. doi: 10.1007/s12032-018-1192-6.

38.

Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care?

Husson O, Younger E, Dunlop A, Dean L, Strauss DC, Benson C, Hayes AJ, Miah A, van Houdt W, Zaidi S, Smith M, Williams J, Jones RL, van der Graaf WTA.

Support Care Cancer. 2019 Mar;27(3):965-980. doi: 10.1007/s00520-018-4386-8. Epub 2018 Aug 28.

39.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

40.

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

van Broekhoven DLM, Verschoor AJ, van Dalen T, Grünhagen DJ, den Bakker MA, Gelderblom H, Bovee JVMG, Haas RLM, Bonenkamp HJ, van Coevorden F, Ten Oever D, van der Graaf WTA, Flucke UE, Pras E, Reyners AKL, Westermann AM, Oldenburger F, Verhoef C, Steeghs N.

Sarcoma. 2018 Jun 21;2018:5982575. doi: 10.1155/2018/5982575. eCollection 2018.

41.

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.

Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.

42.

Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study.

Timbergen MJM, van de Poll-Franse LV, Grünhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, Husson O.

Qual Life Res. 2018 Dec;27(12):3097-3111. doi: 10.1007/s11136-018-1931-3. Epub 2018 Jul 16. Review.

43.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

44.

Targeted Therapy-based Combination Treatment in Rhabdomyosarcoma.

van Erp AEM, Versleijen-Jonkers YMH, van der Graaf WTA, Fleuren EDG.

Mol Cancer Ther. 2018 Jul;17(7):1365-1380. doi: 10.1158/1535-7163.MCT-17-1131. Review.

45.

Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.

Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx MAW, Takes RP, Kaanders JHAM, Groenen PJTA, Flucke UE, van Herpen CML.

Oral Oncol. 2018 Jul;82:29-33. doi: 10.1016/j.oraloncology.2018.04.022. Epub 2018 May 11.

46.

Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies.

Husson O, Huijgens PC, van der Graaf WTA.

Blood. 2018 Jul 26;132(4):385-392. doi: 10.1182/blood-2017-11-778555. Epub 2018 Jun 12. Review.

PMID:
29895664
47.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv68-iv78. doi: 10.1093/annonc/mdy095. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267.

48.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67. doi: 10.1093/annonc/mdy096. No abstract available. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269.

49.

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.

Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, Thomas K, Moskovic E, Szucs Z, Benson C, Messiou C.

Clin Sarcoma Res. 2018 May 14;8:13. doi: 10.1186/s13569-018-0100-3. eCollection 2018.

50.

Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: Results from the PROFILES Registry.

Mols F, Schoormans D, Smit JWA, Netea-Maier RT, Links TP, van der Graaf WTA, Husson O.

Head Neck. 2018 Oct;40(10):2235-2245. doi: 10.1002/hed.25325. Epub 2018 May 13.

PMID:
29756245

Supplemental Content

Loading ...
Support Center